Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(1-Hydroxyheptane-1,1-diyl)bis(phosphonic acid) is a synthetic small molecule belonging to the bisphosphonate class of compounds. It contains two phosphonate groups attached to a heptane backbone and is structurally related to other bisphosphonates used in medicine for bone disorders. Its primary mechanism of action is inhibition of farnesyl pyrophosphate synthase—an enzyme critical in the mevalonate pathway—which disrupts osteoclast-mediated bone resorption. This compound has not been approved for medical use and remains experimental; it has no known clinical indications or completed clinical trials as of June 2025[2][7]. It may be studied as a research tool or specialty chemical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (1-hydroxyheptane-1,1-diyl)bis(phosphonic acid).